Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A

Intervirology

Volumn 47, Issue 2, 2004, Pages 65-71

  Tarao, Kazuo ^a   Rino, Yasushi ^b   Ohkawa, Shinichi ^a   Endo, Osamu ^c   Miyakawa, Kaoru ^a   Tamai, Setsuo ^a   Hirokawa, Satoru ^a   Masaki, Takahiro ^a   Nagaoka, Tadashi ^a   Okamoto, Naoyuki ^a   Tanaka, Katsuaki ^b   Tarao, Norio ^d  

^a KANAGAWA CANCER CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Okinawa Prefectural College of Nursing   (Japan)

^d SEIREI CHRISTOPHER UNIVERSITY   (Japan)

Author keywords

Alanine aminotransferase; Hepatitis C virus associated cirrhosis; Hepatocarcinogenesis; Prevention of hepatocellular carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; ECHOGRAPHY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL; VIRUS CARCINOGENESIS;

ALANINE TRANSAMINASE; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

HEPATITIS C VIRUS;

EID: 3042689587     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077828     Document Type: Article

References (34)

1. Lavanchy D: Hepatitis C: 170 million infected worldwide and still no vaccine (press release No 36). World Health Organization, May 1, 1998.
2. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K: Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990;12:680-687.
3. Ikeda K, Saito S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
4. Kaneko S, Unoura M, Takeuchi M, Terasaki S, Ogino H, Matsushita E, Kobayashi K: The role of hepatitis C virus in hepatocellular carcinoma in Japan. Intervirology 1994;37:108-113.
5. Munoz N, Bosch S: Epidemiology of hepatocellular carcinoma; in Okuda K, Ishak KG (eds): Neoplasms of the Liver. Tokyo, Springer, 1987, pp 3-19.
6. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, Aoki H, Imada T, Shindo K, Okamoto N, Totsuka S: Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999;86:589-595.
7. Tarao K, Iwamura K: Influence of long-term administration of serum albumin on the prognosis of liver cirrhosis in man. Tokai J Exp Clin Med 1983;8:71-78.
8. Fischer JE, Funovics LM, Aguirre A, James JH, Keane JM, Wesdrop RIC: The role of plasma amino acids in hepatic encephalopathy. Surgery 1975;78:276-290.
9. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB: The effects of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976;80:77-91.
10. Yoshida T, Muto Y, Moriwaki H, Yamamoto M: Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn 1989;24:692-698.
11. The San-In Group of Liver Surgery: Long-term administration of branched chain amino acids after curative resection of hepatocellular carcinoma; A prospective randomaized trial. Br J Surg 1999;84:1525-1531.
12. Child CG 3rd, Turcotte JG: Surgery and portal hypertension; in Dunphy JE (ed): The Liver and Portal Hypertension. Philadelphia, WB Saunders, 1964, vol 50.
13. Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, Konno T, Iwamoto S, Ohnishi K, Okuda K: Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:10-24.
14. Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M: Ursodiol in the long-term treatment of chronic hepatitis: A double-blind multicenter clinical trial. J Hepatol 1993;19:459-464.
15. Hirayama C, Okumura M, Tanikawa K, Yano M, Mizuta M, Ogawa N: A multicenter randomized control clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-719.
16. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C: Effects of glycyrrhizin on biochemical tests in patiens with chronic hepatitis - Double-blind trial. Asian Med J 1983;26:423-438.
17. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al: The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-1500.
18. Oka H, Yamamoto S, Kuroki T, Harihara S, Marumo T, Kim SR, et al: Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76:743-749.
19. Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, Kojiro M: The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 1994;54:448-454.
20. Slaga TJ, Scribner JD: Inhibition of tumor initiation and promotion by anti-inflammatory agents. J Natl Cancer Inst 1973;51:1723-1725.
21. Cameron R, Lee G, Farber E: Chemical mitogens as effective alternatives to partial hepatectomy in the new model for the sequential analysis of hepatocarcinogenesis. Proc Am Assoc Cancer Res 1978;19:56.
22. Marks F, Bertsch S, Grimm W, Schweizer J: Hyperplastic transformation and tumor promotion in mouse epidermis: Possible consequences of disturbances of endogenous mechanism controlling proliferation and differentiation; in Slaga TJ, Sivak A, Boutwell RK (eds): Carcinogenesis. New York, Raven, 1978, vol 2, pp 97-116.
23. Argyris TS: Tumor promotion by damage-induced epidermal hyperplasia in the skin of mice. Proc Am Assoc Cancer Res 1979;20:4.
24. Gratzner HG: Monoclonal antibody to 5-bromo-and 5-iodo-deoxyuridine: A new reagent for detection of DNA replication. Science 1982;218:474-476.
25. Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y, Tamai S, Hoshino H, Inoue T, Kanisawa M: Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 1994;73:1149-1154.
26. Tarao K, Shimizu A, Ohkawa S, Harada M, Ito Y, Tamai S, Kuni Y, Okamoto N, Inoue T, Kanisawa M: Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology 1992;103:595-600.
27. Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y, Harada M, Ito Y, Tamai S, Akaike M, Sugimasa Y, Takemiya S, Okamoto T, Okamoto N: Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res 1994;85:1040-1044.
28. Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, Tsuneyoshi M: Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775.
29. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, Tanabe H, Shimizu A, Yoshida M, Kakita A: Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associatied cirrhosis and HCC. Cancer 1997;79:688-694.
30. Zelman S, Wang CC: Transaminases in serum and liver correlated with liver cell necrosis in needle aspiration biopsies. Am J Med Sci 1959;237:323-334.
31. Schmidt E, Schmid FW, Wildhirt E: Aktivitäts-Bestimmungen von Enzymen des energieliefernden Stoffwechsels in menschlichen Serum und in Leberpunktaten bei Leberkrankungen. Klin Wochenschr 1958;36:280-287.
32. Baier H, Hennemann G, Mühler E: Beitrag zur Aktivitä tsbeurteilung chronischer Leberekrankungen durch Bestimmung von Serumenzymen. Klin Wochenschr 1961;39:117-119.
33. Tarao K, Shimizu A, Ohkawa S, Tamai S: Prediction of the development of hepatocellular carcinoma from HCV associated liver cirrhosis (in Japanese). J Jpn Soc Int Med 1995;84:1985-1991.
34. Tarao K, Tamai S, Ohkawa S, Miyakawa K, Aoki H, Takashimizu S, Kagawa T, Watanabe N, Matsuzaki S: The effects of combined drug therapy on the serum alanine aminotransferase levels in HCV-associated liver cirrhosis (in Japanese). Rinsho-to-Kenkyu 1998;75:1858-1867.